Tucatinib is an investigational oral, potent, small molecule tyrosine kinase inhibitor that is highly selective for HER2 and is in a pivotal registration trial in HER2+ metastatic breast cancer.

Therapeutic indications
Type of product
  • Phase
    Phase II started
  • Partnering status
    Not partnered

You may also be interested in